The C-POST trial showed a disease-free survival benefit with adjuvant Libtayo for high-risk cutaneous squamous cell carcinoma, potentially influencing future standard care. Immunotherapy remains the ...
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.
9don MSN
New atlas that charts tumor cell diversity could guide personalized therapy for head and neck cancer
Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results